Literature DB >> 18491124

Aqueous humor concentration of voriconazole after topical administration in rabbits.

Christian K Vorwerk1, F Streit, L Binder, S Tuchen, C Knop, W Behrens-Baumann.   

Abstract

OBJECTIVES: Voriconazol is a triazole antifungal drug with in vitro fungicidal activity against all Candida spp., Fusarium spp. and Aspergillus spp. which are frequent causes of fungal keratitis depending on geographic location. We investigated the penetration of voriconazole through the cornea into the aqueous humor (AH) after topical administration.
METHODS: A 1% voriconazole solution was applied onto each rabbit's cornea. Topical drug application was processed at different time intervals: single drug application with AH sampling after 30 min, 1 h, 2 h, 3 h and 6 h. In addition, we evaluated AH samples after repeated topical application of voriconazole every 30 min after 1, 2, 4 and 6 h. Furthermore, after repeated drug application every hour, we analyzed voriconazole concentration after 2, 3, 4 and 6 h. All samples were analyzed by high-performance liquid chromatography (HPLC)-UV.
RESULTS: A single application showed a maximum peak in AH of 3.58 microg/ml (N = 9) after 30 min. Within 3 h the concentration decreased to 0.04 microg/ml (N = 11). Application of voriconazole every half an hour revealed a peak value of 6.73 microg/ml (N = 10) after 2 h; after 4 h the value decreased to 6.19 microg/ml (N = 10) and was constant after 6 h (6.12 microg/ml, N = 6). When administrated every hour, only lower AH concentrations of voriconazole were reached with a maximum level of 2,06 microg/ml (N = 8) after four hours.
CONCLUSION: In AH, therapeutic drug levels that cover the minimum inhibitory concentrations (MIC) of most fungi can be reached. To achieve a sustained high level of voriconazole as an effective antifungal therapy for corneal keratitis, voriconazole should be topically administered every 30 min.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491124     DOI: 10.1007/s00417-008-0849-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  15 in total

Review 1.  Fungal and parasitic infections of the eye.

Authors:  S A Klotz; C C Penn; G J Negvesky; S I Butrus
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection.

Authors:  Judy E Kim; Stephen L Perkins; Gerald J Harris
Journal:  Arch Ophthalmol       Date:  2003-05

3.  Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.

Authors:  Rocus R Klont; Cathrien A Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2005-05-12       Impact factor: 9.079

4.  Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.

Authors:  Michael A Thiel; Annelies S Zinkernagel; Jürgen Burhenne; Claude Kaufmann; Walter E Haefeli
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

5.  Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses.

Authors:  Alison B Clode; Jennifer L Davis; Jacklyn Salmon; Tammy Miller Michau; Brian C Gilger
Journal:  Am J Vet Res       Date:  2006-02       Impact factor: 1.156

6.  Voriconazole and fungal keratitis: a report of two treatment failures.

Authors:  JoAnn A Giaconi; Fabiana B Marangon; Darlene Miller; Eduardo C Alfonso
Journal:  J Ocul Pharmacol Ther       Date:  2006-12       Impact factor: 2.671

7.  Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.

Authors:  Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.

Authors:  Güliz Fatma Yavas; Faruk Oztürk; Tuncay Küsbeci; Zafer Cetinkaya; Sitki Samet Ermis; Nuri Kiraz; Umit Ubeyt Inan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-02       Impact factor: 3.117

9.  Management of tunnel fungal infection with voriconazole.

Authors:  Vishal Jhanji; Namrata Sharma; Rashim Mannan; Jeewan S Titiyal; Rasik B Vajpayee
Journal:  J Cataract Refract Surg       Date:  2007-05       Impact factor: 3.351

10.  Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.

Authors:  Seenu M Hariprasad; William F Mieler; Eric R Holz; Hua Gao; Judy E Kim; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2004-01
View more
  6 in total

1.  [Fusarium keratitis with dramatic outcome].

Authors:  J Lübke; C Auw-Hädrich; T Meyer-Ter-Vehn; E Emrani; T Reinhard
Journal:  Ophthalmologe       Date:  2017-05       Impact factor: 1.059

2.  Voriconazole-refractory fungal infection of phacoemulsification tunnel.

Authors:  Vikas Mittal; Ruchi Mittal; P C Sharma
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

3.  Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.

Authors:  C M Martín-Navarro; A López-Arencibia; F Arnalich-Montiel; B Valladares; J E Piñero; J Lorenzo-Morales
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-19       Impact factor: 3.117

Review 4.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

5.  Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis.

Authors:  Randa S Haddad; Georges M El-Mollayess
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

Review 6.  Fusarium Keratitis-Review of Current Treatment Possibilities.

Authors:  Marek Szaliński; Aleksandra Zgryźniak; Izabela Rubisz; Małgorzata Gajdzis; Radosław Kaczmarek; Joanna Przeździecka-Dołyk
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.